New publication on Real-world effectiveness of dupilumab in A European cohort of CRSwNP

We are excited to share our latest research assessing the real world impact of dupilumab on a large CRSwNP patient cohort across six European tertiary care centers. Research was performed togehter with Sven Seys and the CHRINOSOR consortium

Key findings:

• Significant Symptom Improvement: Dupilumab treatment led to marked improvements in nasal polyp score (NPS), quality of life (SNOT-22) and symptom scales (smell, sinus blockage). OUtcomes improved substantially by both 24 and 52 weeks.
• High Response Rate: At 52 weeks, 68.2% of patients met all 4 of the more stringent EUFOREA response criteria, underscoring the sustained, robust impact of dupilumab

This study highlights dupilumab as an effective and durable treatment option for patients with CRSwNP, regardeless of comorbidities or baseline type 2 inflammation levels.